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Background: The prevalence of atrial fibrillation (AF) is growing as the population ages, and at least 15% of
ischemic strokes are attributed to AF. However, many high-risk AF patients are not offered guideline-recommended
stroke prevention therapy due to a variety of system, provider, and patient-level barriers.
Methods: We will conduct a pragmatic, cluster-randomized controlled trial randomizing primary care clinics to
test a “toolkit” of quality improvement interventions in primary care. In keeping with the recommendations of the
chronic care model to simultaneously activate patients and facilitate proactive care by providers, the toolkit includes
provider-focused strategies (education, audit and feedback, electronic decision support, and reminders) plus
patient-directed strategies (educational letters and reminders). The trial will include two feedback cycles at baseline
and approximately 6 months and a final data collection at approximately 12 months. The study will be powered to
show a difference of 10% in the primary outcome of proportion of patients receiving guideline-recommended
stroke prevention therapy. Analysis will follow the intention-to-treat principle and will be blind to treatment
allocation. Unit of analysis will be the patient; models will use generalized estimating equations to account for
clustering at the clinical level.
Discussion: Stroke prevention therapy using anticoagulation in patients with AF is known to reduce strokes by two
thirds or more in clinical trials, but most studies indicate under-use of this treatment in real-world practice. If the
toolkit successfully improves care for patients with AF, stakeholders will be engaged to facilitate broader application
to maximize the potential to improve patient outcomes. The intervention toolkit tested in this project could also
provide a model to improve quality of care for other chronic cardiovascular conditions managed in primary care.
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Atrial fibrillation (AF) is a common and preventable
cause of stroke [1]. The prevalence of AF is approxi-
mately 1% overall, but it accounts for 15% of all ischemic
strokes and 33% of strokes in the elderly [2]. Such
strokes result in permanent disability in 60% and death
in 20% [3]. Aspirin reduces the relative risk of stroke in
patients with AF by approximately 20–30% while antico-
agulants reduce the relative risk of stroke in patients
with AF by approximately 60–70% [4–7]. The traditional
anticoagulation option, vitamin K antagonist (warfarin),
may increase risk of bleeding [8, 9], has a narrow thera-
peutic index, and requires frequent blood tests (to moni-
tor the international normalized ratio (INR) level) but
remains an effective therapeutic option [8, 10]. Novel
oral anticoagulants (NOACs) (e.g., dabigatran, rivaroxa-
ban, apixaban) do not require blood monitoring as fre-
quently and have been shown to have similar or superior
efficacy to warfarin, lower rates of intracranial hemorrhage
[11], and in some cases, reduced risk of bleeding [12]. The
2014 Canadian Cardiovascular Society (CCS) updated
guidelines for atrial fibrillation emphasize that the vast
majority of patients with AF would likely benefit from
anticoagulation to reduce risk of stroke [13].
Despite the evidence that many AF-related strokes are
preventable with proper therapy, the proportion of eli-
gible patients receiving appropriate stroke prevention
therapy remains far too low. A 2010 systematic review of
54 studies conducted around the world found that 50%
of patients with AF at high risk of stroke did not receive
anticoagulation [14]. A population-based study of pa-
tients over age 65 in Alberta published in 2011 found
that only 49% of patients with a diagnosis of AF received
anticoagulation, with no difference among those with
highest and lowest risk of stroke [15]. A retrospective
study in Ontario of hospitalizations for ischemic stroke
between 2003 and 2007 showed that among a very high-
risk group of patients with AF, a previous ischemic
stroke or transient ischemic attack (TIA), and no known
contraindications to anticoagulants, only 18% were re-
ceiving warfarin and in the desirable INR range on pre-
admission [3]. Despite recent studies showing increase
in use of oral anticoagulants (OAC) [16–18], anticoagu-
lation therapy still remains suboptimal among patients
with AF [19–22].
Reasons for suboptimal care
Barriers to appropriate stroke prevention therapy may
be present at the levels of the system, physician, and pa-
tient [23]. At the system level, specialized anticoagula-
tion clinics may be associated with improved processes
of care, [24] but are not available to most patients. A
2011 systematic review [25] concluded that a well-
coordinated, structured approach is necessary for safeand effective management of anticoagulation, noting that
this could occur in primary care [26]. Unfortunately, a
Canadian survey of primary care clinics found inad-
equate coordination with laboratories, INR tracking sys-
tems, and use of reminders [27]. As a result, patients
taking warfarin in Ontario are outside the therapeutic
window up to 40% of the time [28]. Some primary care
clinics have developed methods to monitor patients tak-
ing warfarin but rely on patients that are committed to
regular blood tests. An ideal system of care would help
primary care providers identify patients who neglect
their blood tests, have discontinued their medications,
or require a reassessment because the risk-benefit ratio
of anticoagulants has changed due to development of
new risk factors.
Even if such systems existed, physician’s knowledge
and attitudes with respect to anticoagulants need to be
addressed. The new CCS guidelines recommend that for
most patients over age 65, the benefit of anticoagulants
will outweigh the risks [13]. A meta-analysis of patient-
level data from 8932 patients, covering 17.685 years of
observation found that the benefit of anticoagulants in-
creased with age, while the risks associated with aspirin
increased with age and outweighed the benefits [29, 30].
However, physicians tend to substantially overestimate
the risk of bleeding associated with anticoagulation, and
to underestimate the benefits [31–33]. This may be be-
cause physicians tend to overestimate fall-risk in the eld-
erly, [34] yet it is estimated that older patients taking
warfarin must fall about 295 times per year for risks to
outweigh benefits [35, 36]. It is important to accurately
estimate the magnitude and severity of risk for both
stroke and bleeding and to help patients weigh these
risks [37]. This is particularly relevant in AF because
AF-related stroke leads to permanent disability (physical
and/or cognitive) in the majority of patients [38], and
quality of life utility scores for stroke have been estimated
to be worse than major bleeding [39]. In day-to-day clin-
ical practice, identifying patients who may require changes
to treatment, weighing risks against benefits, and commu-
nicating these risks to patients are time consuming and
difficult [40].
A prospective, observational Canadian study found that
patients with AF placed more value on the avoidance of
stroke and less value on the avoidance of bleeding than
their physicians [41]. In the context of under-use of formal
risk assessment tools and anticoagulants, it is plausible
that new tools supporting an evidence-informed, shared
decision-making process with patients may lead to in-
creased utilization of anticoagulants [42, 43]. The recent
release of new guideline recommendations, the evidence
that specific barriers are leading to suboptimal quality of
care, and the presence of new medications emphasize the
need for a comprehensive approach to knowledge
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ment for this high-risk condition.
Previous relevant trials aiming to improve stroke
prevention therapy in AF
Three previous trials focused on patients using decision
aids. A UK study that compared a computerized decision
aid to printed guideline-based recommendations found
decreased use of warfarin among low-risk patients but
was unsuccessful in increasing its use among high-risk
patients [44]. Two Canadian studies that compared pa-
tient decision aids to no intervention resulted in no
change in the use of warfarin [36, 45]. One of these
studies did observe an improvement in stroke preven-
tion therapy at 3 months but no difference at 12 months
[45], suggesting the need for longer-term strategies. A
multifaceted approach that includes reminders for ad-
herence might be more effective for long-term anticoa-
gulation. Since risks change over time and because
persistence with anticoagulation is known to decline
significantly over time, longitudinal, multifaceted inter-
ventions may be more likely to improve uptake of
stroke prevention therapy.
Two previous trials directed at providers have
attempted to increase anticoagulation in patients with
AF. One cluster-randomized trial in the USA compared
audit and feedback against audit and feedback plus out-
reach visits and learning collaborative meetings, aiming
to improve a variety of processes related to cardiovascu-
lar risk management [46]. There was no change in the
rate of oral anticoagulation [46]. In another cluster-trial
in the UK, investigators adapted guidelines and pro-
moted them in educational meetings led by opinion
leaders, as well as outreach visits [47]. There was a 10%
increase in the proportion of patients with guideline-
concordant stroke prevention, but the study was powered
to find a 20% increase. Currently, two large cluster-trials
are underway in Australia involving specialist support
regarding specific cases and telephone-based educa-
tional outreach [48, 49]. Given the lack of studies con-
ducted since NOACs have come to market, the results
of these educational interventions will be of great inter-
est. Yet, even if knowledge is addressed among pro-
viders and patients, sustained improvements in stroke
prevention therapy cannot be achieved without ad-
dressing other barriers.
At the system level, “NHS Improvement” in the UK
has identified AF as a priority topic, [50] encouraging
appropriate stroke prevention therapy and providing
tools to enable audit of anticoagulation use in patients at
each risk level. In 2013, new quality outcomes frame-
work benchmarks in the UK were implemented to en-
courage formal stroke risk assessment and use of
anticoagulation [51]. Another approach was illustratedin a Dutch trial of a nurse-run, guideline-based specialty
clinic for AF patients, which led to a statistically signifi-
cant decrease in cardiovascular mortality compared to
usual care (1.1% versus 3.9%), with no difference in
major bleeding (1.7% in each arm) [52]. This supports
the concept of interventions implementing standardized
processes for patients with AF, but specialized clinics are
not likely to be available to most patients with AF.
There is a need for quality improvement initiatives that
simultaneously addresses provider-level, patient-level,
and organization-of-care-related barriers in primary
care. The objective of this study is to test a “toolkit” of
quality improvement interventions that aims to incorp-
orate best evidence regarding its components and tailor
intervention design to known determinants of stroke
prevention treatment in primary care.
Methods
Study design
This is a pragmatic, cluster-randomized trial with two
parallel arms and outcome analysis blinded to allocation.
The cluster design was chosen to account for multi-
physician clinics and to determine the effects at the
patient level, provider levels. The protocol is registered
at clinicaltrial.gov (NCT01927445). The Sunnybrook
Health Sciences Centre research ethics office approved
the study (075–2013). This trial will be conducted in
conjunction with a similar study focused on chronic kid-
ney disease (CKD) whereby the intervention group for
this trial will serve as the control group for the CKD trial
and vice versa (i.e., an “active-control” trial). Therefore,
the randomization must take into account covariates
related to CKD.
Participants
Participants will be drawn from the primary care prac-
tices associated with the Electronic Medical Record
Administrative data Linked Database (EMRALD) in On-
tario, Canada. EMRALD is a unique data source that
captures complete clinical patient charts already being
used by family physicians (thereby avoiding the need for
case report forms) [53, 54]. The electronic medical rec-
ord (EMR) data are extracted and securely stored at the
Institute for Clinical Evaluative Sciences (ICES), where it
can be linked to population-level administrative health
databases. EMRALD provides an opportunity for large-
scale initiatives by facilitating centralized, automated
chart abstraction, and data analysis using validated data-
base algorithms to assess and provide feedback regarding
quality of care. The platform has been used before to
facilitate a quality improvement trial [55].
Eligible physicians are those participating in EMRALD,
using PS Suite® EMR for at least 2 years, and have 100
or more rostered patients. These eligibility criteria are to
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with their EMR and have adequate patient data to assess
baseline and outcome measures. Eligible patients within
EMRALD will have a physician diagnosis of AF recorded
in their chart and >18 years of age. No distinction will
be made between paroxysmal, persistent, and permanent
AF. Analysis will be restricted to adult patients rostered
to participating physicians since physicians may not start
long-term medications for patients who are not regularly
seen at their practice (thus excluding encounters such as
“walk-in” patient visits).
At study commencement, 194 eligible physicians from
34 clinics with a total roster of 140,147 adult patients
contributed data to EMRALD. These clinics are located
across Ontario in urban, semi-urban, and rural settings.
Comparisons conducted at ICES of the patient popula-
tion of EMRALD physicians to the general primary care
population in Ontario show that they are similar with re-
spect to age and sex [56]. Participating physicians in
EMRALD have access to the System for Audit and Feed-
back to Improve caRE (SAFIRE). SAFIRE is a secure,
password-protected website used to provide perform-
ance feedback reports regarding quality of care for
chronic disease. Data are available at both the aggregate
and patient-specific levels. Prior to this trial, SAFIRE fo-
cused on comparing actual to guideline-recommended
practice for patients with hypertension, diabetes, and/or
ischemic heart disease. Physicians are able to compare
their performance to other physicians that participate in
EMRALD, and for physicians practicing in a group prac-
tice, physicians are able to compare their performance to
other physicians within their own clinic, and their clinic
performance compared to other clinics that participate
in EMRALD.
Allocation
To avoid contamination, all physicians (and patients) be-
longing to a practice with shared administrative resources
will be randomly assigned in a cluster to the intervention
or control arm. The allocation will be done centrally based
on clinic (clusters) by an analyst to ensure concealmentTable 1 Matching barriers to intervention components
Examples of barriers to stroke prevention treatment
Other patient issues may distract from AF management
Provider awareness of new guidelines
Provider attitudes regarding bleeding risk with anticoagulants
Provider assessment and communication of risk/benefit
Systems to monitor performance against standards and to
identify patients without treatment
Systems to monitor patients on treatment
Systems to identify patient non-adherencefrom the study investigators. Restricted randomization has
been recommended for cluster trials when baseline data
is available [57]. We will use minimization [58] to
evenly distribute clinics across trial arms and to im-
prove balance across the following baseline covariates
using the free software “MINIM” [59]: the total number
of primary care physicians in each clinic, number of pa-
tients over 65 years, average age of all patients, rural lo-
cation, average years of experience, average years on
the EMR, number of patients with hypertension, num-
ber of patients with ischemic heart disease, number of
patients with diabetes, number of patients with atrial
fibrillation, number of patients with stage 3+ CKD,
number of patients meeting blood pressure target (140/
90 or 130/80 if patient has diabetes), number of pa-
tients 65 and older with atrial fibrillation or have a
CHADS2 ≥ 1 and an anticoagulation prescription, and
number of patients between 50 and 80 years of age
with stage 3+ CKD on a statin unless contraindicated.
Using baseline data from the participating clinics, con-
tinuous variables will be classified as high or low using
the median value as the cut-point. Unlike stratification,
increasing the number of covariates in minimization
does not lead to increased risk for imbalance [60]. The
participating practices will be minimized simultan-
eously at the initiation of the trial, reducing risk of
selection bias.
Intervention
The control arm will receive “usual care” without any at-
tempt to standardize treatment. Usual care clinics will be
unaware of a study focusing on atrial fibrillation, and will
continue to receive audit and feedback regarding their pa-
tients with other clinical conditions [55]. However, guide-
lines do not self-implement, and many trials of guideline
implementation interventions are not successful in im-
proving care [61]. This is in part explained by poor match-
ing of interventions to barriers [62]. Thus, we have
developed a multifaceted knowledge translation program
to address many of the known barriers to optimal stroke
prevention therapy (Table 1). A multidisciplinary teamStrategies for quality improvement
EMR AF toolbar reminder
Educational materials
Educational materials, risk calculator
EMR risk tool added to each relevant patient chart with
summary statements
Audit and feedback with patient-level data
EMR AF treatment flow chart
EMR searches and reminders
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nists, a pharmacist, graphic designers, and an EMR pro-
grammer provided input over the course of 2 years to
refine the intervention components. During this time, we
considered the literature regarding barriers to optimal
stroke prevention therapy and how these could be ad-
dressed using feasible, evidence-based approaches. A pilot
of the strategies in the intervention toolkit was conducted
in a large primary care clinic where a co-investigator
works as a family physician (AV) [17, 63]. We used con-
tinuous quality improvement methods, using rapid plan-
do-study-act cycles to iteratively optimize the EMR tool
format and design to ensure they met the needs of busy
primary care clinicians. Evaluation of this pilot was mixed
methods, including observed use of the tools and semi-
structured interviews with 14 patients-provider dyads to
assess usability of the EMR tools and preferences regard-
ing implementation support [63].
The resulting multifaceted intervention will be pre-
sented to recipients in clinics of the intervention arm as
a toolkit. A pragmatic approach will be taken in which
providers and clinics will be welcome to use whichever
aspects of the toolkit they choose. Below, we describe
the evidence base for selection of the intervention
components and the approach used to deliver them
in this trial.
Printed educational materials for physicians
A Cochrane systematic review found that printed educa-
tional materials may have a beneficial effect on profes-
sional practices (median 4.3% increase in intended
processes, interquartile range (IQR) −8.0 to 9.6%) [64].
Working with a multidisciplinary team of clinicians and
designers, we have developed “AFib in One Page,” a
summary of AF guideline recommendations relevant to
primary care (http://afibreno.uhnopenlab.ca/wp-content/
uploads/2014/10/afonepage.pdf ). We will also append a
one-page series of questions and answers specifically de-
veloped to provide brief evidence-based statements ad-
dressing the knowledge-related barriers described above
(e.g., how to account for risk of bleeding due to risk of
falling in the elderly) (http://afibreno.uhnopenlab.ca/wp-
content/uploads/2014/11/faq.pdf ). To validate the accur-
acy and utility of the educational material, input was
sought from a multidisciplinary team including members
of the CCS guideline committee.
Audit and feedback
A Cochrane systematic review found that audit and feed-
back increases healthcare professionals’ compliance with
desired practice by 4.3% (IQR 0.5 to 16%) [57]. We have
experienced conducting trials featuring audit and feed-
back to family physicians, having recently completed a
2-year trial in which participants received data regardingthe proportion of patients with diabetes and/or heart
disease meeting evidence-based targets [55]. Both aggre-
gate and individual-level data will be provided using data
from the physician’s own electronic patient charts
through SAFIRE.
Performance will be compared against the median
score of the top ten percent of peers, an evidence-based
approach to provide an achievable benchmark of care
[65]. In addition, drop-down menus allow the user to ag-
gregate the data for all physicians in the practice and
compare this to all other intervention practices to facili-
tate practice-level quality improvement strategies (see
Figs. 1a, b for example feedback reports). The design of
these reports will match those already delivered to all
EMRALD participants (diabetes, heart disease, and
hypertension) in addition to AF reports. Both raw num-
bers and tables are used to help users visualize achieve-
ments of quality indicators (and change over time).
Based on a qualitative process evaluation of the afore-
mentioned trial [66], the feedback presents both achieve-
ments of best-practice quality indicators, and of patients
exceeding high-risk thresholds. The patient-level data
can be used to sort by patients, any of the quality indica-
tors, or high-risk thresholds. There is also an opportun-
ity for users to exclude individual patients from future
reports (see Fig. 1c).
Physicians (or their assigned delegate) can sign into a se-
cure online platform to retrieve their data. New audits will
be conducted every 6 months and feedback reports are
typically available 1–3 months after data are collected.
Continuing medical education (CME) credits are available
to users who review the data and complete a worksheet
that suggests possible action plans for each clinical condi-
tion (i.e., ask front office staff to arrange an appointment
to discuss treatment options [see Additional file 1 for
example worksheet]). EMRALD participants receive
email notices when updated feedback is available. The
emails will include instructions for delegates (usually a
nominated administrative person in each clinic) to
download and create a prioritized list of patients who
may benefit from reassessment (e.g., those with
CHADS2 > 1 and no anticoagulation or no recent blood
pressure measurement).
EMR-based clinical decision support and reminders
A recent systematic review of randomized trials found
electronic clinical decision support systems increased
the proportion of providers making appropriate pre-
scriptions (odds ratio 1.57; 95% confidence interval (CI),
1.35 to 1.82). Although government-funded initiatives
have been effective at increasing uptake of EMR systems
in primary care in Ontario, there is a large division
between simply using EMR as an electronic means of
storing records and leveraging EMR data for enhancing
ab
c
Fig. 1 Examples of System for Audit and Feedback to Improve caRE reports. a System for Audit and Feedback to Improve caRE example of
aggregate-level feedback report for atrial fibrillation at target. b System for Audit and Feedback to Improve caRE example of aggregate-level feedback
report for atrial fibrillation: high risk. c Example of patient-specific feedback for atrial fibrillation
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[67]; national surveys suggest that <15% of Canadian
providers are leveraging EMR data to support quality
improvement [68]. Therefore, we will provide simple-to-
use EMR tools that can be easily activated within the
charts of patients with AF at the point of care. Further
information regarding coding and/or functionality of the
tools below can be shared upon request:
(a)AF toolbar (Fig. 2a): The AF toolbar is a reminder
system to prompt physicians to address AF when





Fig. 2 Screenshots of electronic medical record tools for atrial fibrillation. a A
initial assessment. c Structured template for atrial fibrillation follow-up visit. d
risk. e Physician reminders for INR tracking and overdue renal function testsreasons. It will appear at the top of the chart of
patients documented to have AF in the cumulative
patient profile of the EMR record and will provide
one-button access to the EMR-based AF tools
described below. The toolbar includes quick-links
to provider resources (e.g., medication dosing
information) and patient handouts that use lay
terms to describe AF, AF treatment, and management
options (http://afibreno.uhnopenlab.ca/?page_id=155).
(b)Templates for initial assessment or routine follow-up
of patients with AF (Fig. 2b, c): Our pilot project
provided strong impetus for the development oftrial fibrillation toolbar. b Structured template for atrial fibrillation
Chart-based clinical decision aid for calculating stroke and bleeding
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prompts regarding the essential items to cover when
seeing a patient with AF and wanted to retain flexibility
to respond to such prompts according to the
competing priorities of a given encounter. With
these principles in mind, we included in the toolkit
EMR-based “custom forms” (i.e., templates) that can
be inserted within the progress note. These follow a
typical SOAP note format (i.e., subjective, objective,
assessment, plan) familiar to family physicians and
facilitate a brief assessment of both quality of life and
adherence to stroke prevention treatment.
(c)AF-related stroke and bleeding risk calculator
(Fig. 2d): Counseling regarding risks and benefits
is challenging, even for patient/provider dyads
with high numeracy. Primary care physicians often
experience discordance when attempting to both
integrate shared decision-making ideals and meet
guideline recommendations [69]. This tool aids the
provider to quickly calculate both risk of stroke with
and without treatment and the risk of bleeding. The
output will remind patients and providers that risk
of stroke and risk of bleeding should not be weighed
evenly, given that impact on quality-adjusted life-years
(QALY) for bleeding is much smaller than for stroke.
(d)Reminders for INR tracking or overdue for renal
function (Fig. 2e): Even if prescribed with warfarin,
evidence suggests that patients may be in
therapeutic range only about half the time [70].
Patients attending anticoagulation clinics with
systematic, protocol-driven approaches to warfarin
dosing spend more time in therapeutic range, while
other physicians may have a tendency to underdose
rather than overdose warfarin [71]. The goal of this
tool is to provide physicians (or pharmacists associated
with intervention clinics) with a system for tracking
patients taking warfarin and assist providers in
adjusting warfarin dose according to the INR result.
Implementation support
A previous study examining a quality improvement
intervention in Ontario found that even multidisciplinary
primary care teams failed to take action upon receiving
feedback reports indicating substandard performance on
chronic disease management due to a lack of “perform-
ance management skill development” [72]. At the same
time, high-cost interventions are unlikely to be scalable or
replicated. Therefore, we aim to offer implementation
support in a manner that could be sustainable, as de-
scribed below.
With notification that the SAFIRE feedback is avail-
able, intervention clinics will be offered a virtual group
presentation (i.e., a webinar) by research team members
familiar with both the toolkit and the clinical aspects ofAF. In advance of this meeting, we will attempt to iden-
tify local physician champions and key non-physician
participants (i.e., data retrieval delegates) at each interven-
tion clinic. The educational aspect of the presentation will
review the guideline summary including approaches for
risk assessment and information about NOACs and then
introduce the functionality of the online feedback plat-
form. Although the feedback is confidential for each phys-
ician, participants will be encouraged to discuss the
results among their teams, providing an opportunity to
problem solve and share best practices. The group presen-
tation will also be used to introduce the EMR-based fea-
tures of the toolkit. Research staff will then provide
support to clinic administrators to install and activate the
EMR-based tools. (The EMR-based reminders or tools
can be “turned off” by the providers at any time.) Any par-
ticipants not able to attend the group meeting will be pro-
vided with a video recording of the webinar and offered a
personal phone meeting with similar objectives. One
month after the initial presentation, each clinic will receive
invitations for one-to-one assistance to troubleshoot any
problems arising with the intervention components and to
offer again help implementing the toolkit. With new
feedback approximately 6 months later, research staff will
contact the physicians via email to prompt them to review
updated feedback reports, an infographic designed to
encourage interest in improving the management of AF
[Additional file 2], as well as to offer support for imple-
menting or using the toolkit.
Outcomes
The primary outcome is the proportion of patients with
AF and an estimated yearly risk of stroke greater than
2% who are receiving stroke prevention therapy after
one year. Specifically, the denominator will be patients
aged ≥ 65 or who have a CHADS2 score ≥ 1. Offering
such patients anticoagulation would be concordant with
the 2014 CCS Guidelines [13]. Although the guidelines
indicate that NOACs may be preferable over warfarin,
we will group all anticoagulants together for the primary
outcome because warfarin remains a suitable option for
many patients. We acknowledge that anticoagulation
may not be advisable in all these patients (e.g., high risk
of bleeding, severe cognitive dysfunction making compli-
ance unreliable, patient preference, etc.). However, it is
impractical to accurately adjudicate appropriateness of
withholding the anticoagulant using chart reviews alone
given variability in charting practices and it is expected
that the trial design will balance such patients across
the study arms.
Secondary outcomes include the proportion of pa-
tients with the following characteristics: no CHADS2
risk factors and age <65 receiving anticoagulation; taking
warfarin with at least six INRs measured per year; taking
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the Rosendaal method [73]; taking a NOAC with appro-
priate dosing (based on age and/or renal function); tak-
ing a NOAC but without renal function measured in 6
or 12 months; receiving other antiplatelets (e.g., aspirin
alone, clopidogrel alone, aspirin plus dipyridamole, as-
pirin plus clopidogrel); taking an oral anticoagulant in
combination with single or dual antiplatelet therapy;
blood pressure (BP) and low-density lipoprotein (LDL)
at target (to assess control of other stroke risk factors).
Process outcomes include the proportion of patients
with AF in the cumulative patient profile, the proportion
of patients with a formal stroke risk assessment com-
pleted, the proportion of patient charts with EMR-based
tools used, and the proportion of providers who accessed
the SAFIRE website to review their quality of care metrics.
Measurement
EMR-based treatment data will be used to identify stroke
prevention therapy. Previous work with EMRALD has
shown that EMR data regarding active treatments (e.g.,
warfarin) is comparable to administrative data in terms
of drug-capture for patients over age 65 (and far super-
ior for patients under age 65 as drug administrative data
in Ontario is limited in patients under 65) [16, 53]. To
determine whether the stroke prevention therapy is con-
cordant with guideline recommendations, the EMR data
will be used to identify whether patients have relevant
comorbidities (i.e., CHADS2 risk factors). The EMRALD
team has validated, automated methods for identifying
patients with diabetes [55, 74], ischemic heart disease
[75], and hypertension [76] using data from both struc-
tured fields and free text. Patients identified with these
conditions and relevant quality indicators are already
included in the online feedback platform.
We developed a strategy for centralized identification
of patients with AF in EMR data by performing a sensi-
tive search for patients with a possible diagnosis of AF
in the patient profile or with relevant treatments and/or
results of cardiology tests that implicate a diagnosis of
AF. An EMRALD team physician verified the charts to
remove false positives from the study cohort, such as
those with only brief runs of AF or those with only tran-
sient AF following surgery and follow-up testing that
was normal. The methods for developing the search are
similar to those used in previous studies [77] and based
on previously described patient populations [16]. This
search algorithm identified AF patients with one or
more of the following components: (1) Recording of AF,
including paroxysmal AF, “fibrillation”, and “flutter” in
the problem list or history of past health fields of the
EMR record [Additional file 3]; (2) electrocardiogram
(ECG) and Holter monitor reporting AF; or (3) OAC
prescription without clot, thrombosis, embolism, DVT,PE, valve replacement in the problem list, or history of
past health fields, in combination with calcium channel
blockers (CCB), ß-blockers, or digoxin prescription. The
algorithm was able to accurately identify AF patients
with a sensitivity of 78.6% (95% CI, 72.6–83.9%), a speci-
ficity of 99.9% (95% CI, 99.8–99.9%), positive predictive
value of 95.1% (95% CI, 90.8–97.7%), and negative pre-
dictive value of 99.4% (95% CI, 99.1–99.5%). In addition,
we developed and validated automated algorithms for
identification of stroke and congestive heart failure to
enable estimation of CHADS2 risk factors [78].
Analysis
Outcomes will be compared at study completion at the
patient, provider, and clinic levels. The analysis will be
carried out on patient level variables using the general-
ized estimating equation approach to control for the ef-
fects of clustering. We will also adjust for the proportion
of patients with guideline-concordant stroke prevention
therapy at baseline and the other variables used in the
minimization, as recommended by Taves [60]. Analysis
will be performed on an intention-to-treat basis, and pa-
tient identifiers will be removed before transferring the
data securely to analysts so that they will be blind to al-
location. We will conduct the analysis as a longitudinal
cohort design to permit exploration of patients whose
treatments changed over time. As a sensitivity analysis,
we will also conduct a repeated cross-sectional analysis
to capture patients with newly developed AF during the
intervention.
In keeping with similar trials in this literature, we con-
sidered a 10% difference in the primary outcome to be
clinically important [48]. We assumed that 50% of pa-
tients with atrial fibrillation assigned to the usual care
arm receive the primary outcome—using a control arm
proportion of 50% is a conservative approach as it pro-
vides the largest sample size estimation. An EMRALD
manual chart review of 7500 randomly selected adult pa-
tient charts discovered 192 patients with AF [16]; this
2.6% prevalence is similar to what has been reported in
other primary care studies [79]. Based on that pilot data,
we estimated that at least 100 patients would be avail-
able in each clinic (cluster). Therefore, using a reported
intra-cluster correlation = 0.029 for warfarin uptake in
patients with AF in primary care clinics [46], setting
alpha = 0.05, and after adding 10% inflation for patient
loss to follow up, 3276 patients (33 clinics) would be
required to have 80% power [80].
Recruitment
All eligible physicians in EMRALD have consented to
participate in the study. Although this intervention is
multifaceted, it is designed to limit the amount of non-
clinical time required by the physicians. The intervention
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ment to the right patient by leveraging available data to
use at the point of care. The toolkit can be discussed with
physicians at a time that suits them. The pragmatic ap-
proach does not require them to participate in ways they
do not think will be valuable. As the investigators do not
intervene directly upon patients, no patient-level consent
process is required. Patients are not directly recruited but
are analyzed if they remain part of the participating physi-
cian’s roster throughout the trial.
Embedded process evaluation
We will be able to assess uptake of our toolkit by meas-
uring the number of physicians and the frequency of
log-ins to the SAFIRE website. We will also be able to
measure the number of clinics that have uploaded our
AF tools into their EMRs and the frequency of use and
the number of physicians that actually used the tools in
their clinical encounters. Finally, we will pursue a quali-
tative study to assess attitudes and barriers to uptake
after the study is completed. Physician participants will
be interviewed about the facilitators, barriers, or chal-
lenges to the uptake of the toolkit. The qualitative as-
sessment and analysis will be informed by Normalization
Process Theory which addresses how new practices are
implemented, routinely embedded, and integrated in




The most important strength of this protocol is the use
of a cluster-randomized trial design to test a clinically
important question for large numbers of patients at high
risk of stroke. The approach is pragmatic, highly valuing
external validity by limiting eligibility criteria and testing
a readily scalable suite of interventions tailored to ad-
dress known barriers to optimal provision of stroke pre-
vention therapy in primary care for patients with AF.
We believe that the flexible toolkit approach will engen-
der a sense that the intervention is partially “ground-up”
(tailored and customized by participants) rather than
completely “top-down” (implemented from the outside
in a standardized fashion) leading to more meaningful
use of the tools.
We acknowledge several potential limitations. First,
the approach to delivering the interventions as a toolkit
will make it difficult to determine which particular tools
are most effective. While this approach will lead to vari-
ation in intervention uptake, it improves external valid-
ity, mimicking the real-world setting where providers
will only adopt strategies perceived as useful in their
context and for their patients. Second, although we have
carefully developed tools to address known barriers, it ispossible that other interventions may be valuable addi-
tions to the current approach or that the tools used will
not be optimally tailored for the context. We have
attempted to partially address this through a pre-trial
phase including a mixed-methods pilot test in which the
entire toolkit was tested in a primary care clinic, in
keeping with the existing guidance for the development
of complex interventions [82]. Third, our primary out-
come is a process measure (i.e., appropriate prescribing)
rather than a patient-oriented measure (e.g., stroke). We
believe this is reasonable given the well-established ef-
fectiveness of stroke prevention therapy and believe this
compromise is necessary given our desire to complete
the analysis in a reasonable time frame. Fourth, our au-
tomated assessment of risk factors will be limited to data
available in the EMR, and there is variation in the chart-
ing habits of family physicians. This may result in chal-
lenges for identification of patients with AF; patients
with AF that cannot be readily identified will not be
included in feedback reports and will not have the AF
toolbar activated in their EMR chart. However, variation in
charting is expected to be independent of randomization
thus limiting risk of misclassification bias. Medications are
entered as a structured variable in the chart and should
not be affected by idiosyncratic data-entry. We recognize
that some primary care clinics may be more likely to refer
management of AF to consultants, but again expect
that such characteristics would be independent of
randomization. Further, if the rate of anticoagulation
is far higher than expected, as seen in some studies
[17], then we may encounter a ceiling effect. It is also
possible that a ceiling effect may be reached due to
external factors, such as attention given to this area
by pharmaceutical companies. However, we may still
find other results of interest in our analysis, including
measures related to safety (i.e., appropriately frequent
blood work). Finally, it is important to note that partici-
pants in EMRALD are a convenience sample of Ontario
family physicians using PS Suite® EMR. This may make it
difficult to generalize to other providers who use different
EMR systems, or to those not using EMR at all. Neverthe-
less, most of the EMR strategies in the toolkit could be
easily adapted to other systems.
Implications
During the trial, the participants of EMRALD (both pa-
tients and providers) stand to benefit through improved
tools and systems to manage this complicated problem
in primary care. Increasing the proportion of patients
with adequate stroke prevention therapy will result in
improved outcomes for patients and for the health care
system. If successful, similar multifaceted strategies may
be developed and tested for other high-risk populations
in this context.
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